. 2014 Dec 11;10(1):64. doi: 10.1186/s13223-014-0064-7

Table 6.

ASA Maintenance therapy, need for resensitization, and sinus surgery during therapy

ASA maintenance	Dose (mg)*	BID (n, %)	TID (n, %)
	325	37/80 (46.3%)	6/80 (7.5%)
	650	37/80 (46.3.)	0/80 (0.0%)
Patients resensitized (n, %)**		30/111 (27.0%)
Sinus surgery during desensitization	1 ^st year (n, %)	2 ^nd year (n, %)	3 ^rd year (n, %)
Sinus surgery during desensitization	15/111 (13.5%)	5/80 (6.3%)	6/80 (7.5%)

Note:

- N = 80 includes all those who achieved desensitization up to 1 year, with 10 lost to follow up, but kept as ‘intention to treat’.

- N = 111, includes all those who initially achieved desensitization.

*Reasons for ASA dose variations included: adverse effects, up- or down-titrated to symptoms or lack thereof, and/or interruption for surgery or illness.

**Reasons for resensitization included: restart post infection, sinus surgery, other surgery, and/or compliance.